Pulmonx’s (LUNG) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Pulmonx (NASDAQ:LUNG) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $14.00 target price on the stock.

A number of other equities research analysts have also recently weighed in on the stock. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pulmonx has an average rating of “Hold” and an average target price of $5.38.

Pulmonx Stock Performance

Shares of LUNG opened at $2.02 on Thursday. The company has a market cap of $83.33 million, a PE ratio of -1.52 and a beta of 0.07. The stock has a 50-day moving average of $1.75 and a 200-day moving average of $1.79. Pulmonx has a one year low of $1.31 and a one year high of $8.12. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.14. The business had revenue of $22.60 million during the quarter, compared to analyst estimates of $21.73 million. Pulmonx had a negative return on equity of 78.35% and a negative net margin of 59.67%. On average, equities research analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

Insider Activity

In other news, CEO Glendon E. French III sold 67,813 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $1.43, for a total transaction of $96,972.59. Following the sale, the chief executive officer owned 1,409,511 shares in the company, valued at $2,015,600.73. This represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 98,265 shares of company stock valued at $140,519 in the last 90 days. Corporate insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Pulmonx

Hedge funds have recently added to or reduced their stakes in the company. Cerity Partners LLC purchased a new stake in Pulmonx during the 4th quarter valued at $27,000. FNY Investment Advisers LLC purchased a new position in shares of Pulmonx in the third quarter worth $29,000. Opal Capital LLC bought a new position in shares of Pulmonx during the fourth quarter valued at $29,000. Regatta Capital Group LLC purchased a new stake in shares of Pulmonx during the fourth quarter valued at $30,000. Finally, Jain Global LLC bought a new stake in Pulmonx in the 3rd quarter worth about $30,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

More Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx beat Q4 expectations — EPS -$0.25 vs. consensus ~- $0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year‑over‑year, signaling operational progress. Read More.
• Positive Sentiment: Closed a five‑year senior secured credit facility with Perceptive Advisors (initial $40M draw; up to $60M total subject to milestones), which refinanced prior debt and extends maturities to 2031 — materially improves near‑term liquidity. Read More.
• Positive Sentiment: Gross margin and cost discipline improved — Q4 gross margin ~78% and operating expenses down ~11% vs. prior year quarter, supporting a clearer path toward profitability if revenue momentum returns. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating (high target), which can attract momentum buyers given large upside vs. current levels. Read More.
• Neutral Sentiment: Management outlined a strategic restructuring and sales‑force changes on the earnings call — intended to re‑accelerate commercial growth but the near‑term impact on procedure volumes is unclear. Read More.
• Neutral Sentiment: Some analysts updated targets (Canaccord trimmed its target but kept a Buy rating) — mixed analyst activity keeps coverage but shows differing views on recovery timing. Read More.
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below consensus (~$94M), implying slower top‑line growth and limiting near‑term upside despite margin improvements. Read More.
• Negative Sentiment: Insider selling was reported (CEO, general counsel and other officers sold shares on March 2), which can increase perceived selling pressure and weigh on sentiment. Read More.
• Negative Sentiment: The new loan carries a high effective cost (SOFR + 7.0% with 3.75% floor and a 2% PIK option) and includes warrants — helpful for liquidity but increases interest burden and potential dilution if exercised. Read More.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.